retatrutide type 2 diabetes phase 2 lancet 2023 rosenstock as a Novel Treatment for Obesity and Recent advances in the treatment

[] Lynam et al [] reported the discrimination and calibration of seven models of type 1 and type 2 diabetes using regression modeling to machine learning

Less common but more serious side effects include pancreatitis (severe or persistent stomach pain, with or without vomiting), gallbladder problems (strong pain after meals, or yellowing of the skin or eyes), increased resting heart rate, and kidney problems

For many women, compounded semaglutide becomes a practical alternative when comparing Ozempic vs compounded semaglutide

Retatrutide is an investigational triple agonist (GIP, GLP-1, and glucagon receptor) not yet approved by the MHRA or EMA, and should only be used within regulated clinical trials or authorised supply channels